Clinical trial · Interventional
Helicobacter Pylori Infection and Gastric Disease in Bhutan: First Community-Wide, Population-Based Study
A Community-based Collaborative Study for Eradication of Helicobacter Pylori and Associated Gastric Cancer in Bhutan
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Background: Helicobacter pylori is a major risk factor for gastric cancer, yet in many developing countries, including Bhutan where gastric cancer incidence is high, access to screening and eradication is limited. The investigators conducted the first large-scale, population-based survey of H. pylori infection and gastric disease in Bhutan to provide baseline data before the launch of a national gastric cancer prevention program. Methods: Permanent residents aged ≥12 years from 24 villages under Dawakha Basic Health Unit II catchment area were enrolled (December 2019-March 2023). H. pylori status was determined by serum IgG testing, gastric atrophy by serum pepsinogen, and endoscopy was offered to high-risk groups.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
| H.Pylori | — | UNRESOLVED | — |
| H Pylori Eradication | — | UNRESOLVED | — |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Rabeprazole Sodium, Amoxicillin Hydrate, Clarithromycin | Drug | — | UNRESOLVED |
| Upper gastrointestinal endoscopy for the H. pylori and serum pepsinogen positive individuals (high risk group of gastric cancer) | Diagnostic Test | — | UNRESOLVED |
| Urea Breath Test for the prevalence of H pylori | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- H pylori positive individual
- description
- H pylori positive individual receiving triple therapy
- interventionNames
- Drug: Rabeprazole Sodium, Amoxicillin Hydrate, Clarithromycin
- Diagnostic Test: Upper gastrointestinal endoscopy for the H. pylori and serum pepsinogen positive individuals (high risk group of gastric cancer)
- type
- EXPERIMENTAL
- label
- H. pylori positive individuals for UBT test
- description
- The H pylori positive individuals are treated by triple therapy. After 6-8 weeks, the eradication is confirmed by using the UBT (13C Urea Breath Test: Beijing Richen-force Science \& Technology Co. Ltd).
- interventionNames
- Device: Urea Breath Test for the prevalence of H pylori
Primary outcomes (2)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 12 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * • Both male and female age 12 years and above in the selected communities for H. pylori infection screening * Both male and female age 18 years and above in the selected communities for H. pylori infection screening, eradication and endoscopy. * Permanent residence of the communities Exclusion Criteria: * Exclusion criteria for screening * Individuals not consenting Exclusion criteria for eradication and endoscopy * Pre-existing medical conditions where triple therapy or endoscopy is not recommended (mainly pregnant women, renal diseases, history of breathing difficulty)
References
Publications (0)
Data not yet available